JBJ. Kenneth Burkus

J. Kenneth Burkus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


J. Kenneth Burkus has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lumbar Spinal Fusions Using a Novel Cellular Bone Matrix Allograft: A Retrospective Review

    by John David Dorchak, Miller Gantt, J. Kenneth Burkus

    Background In lumbar spinal arthrodesis surgery, bone graft substitutes are used to avoid the complications and limitations associated with autologous iliac crest bone grafts (ICBGs). Cellular allogeneic bone matrices (CBMs) are used as a biologic replacement for iliac crest bone grafts in lumbar spinal fusions. Advanced cryopreservation techniques utilized during allograft processing have been used to retain native viable mesenchymal stem cells (MSCs) and other osteoprogenitor cells available for transplantation. Methods A consecutive series of fourteen patients (eight males and six females) with a mean age of 60 years (range 40 to 78 years) who underwent single- or two-level lumbar interbody fusion (LLIF) using a cellular allogeneic bone matrix as the sole bone graft material were retrospectively reviewed. All patients were followed for a minimum of twelve months, and preoperative, three-, six- and twelve-month postoperative data were assessed. Lumbar fusion status was evaluated by plane and dynamic radiographs. Discussion All patients showed successful radiographic fusion at six months after surgery with evidence of bridging trabecular bone across the interspace. There was no deterioration in fusion status between six and twelve months; all patients remained fused. There was no evidence of implant migration or subsidence. No adverse events were identified at surgery or during the course of follow-up. Improvement in back and leg pain symptoms were identified in all patients; there was no documented loss of neurological function. The use of a cellular allogeneic bone matrix provided sufficient biologic support for successful lumbar spinal interbody fusions.

  • Open Access

    Lateral lumbar interbody fusion using a cellular allogeneic bone matrix in the treatment of symptomatic degenerative lumbar disc disease and lumbar spinal instability

    by William C. Tally, H. Thomas Temple, J. Kenneth Burkus

    Lateral lumbar interbody fusion using a cellular allogeneic bone matrix in the treatment of symptomatic degenerative lumbar disc disease and lumbar spinal instability William C. Tally, H. Thomas Temple, J. Kenneth Burkus


  • Thursday, September 27, 2018 3:35 PM–5:05 PM Section on Motion Technology Abstract Presentations

    by Matthew F. Gornet, J. Kenneth Burkus, Mark E. Shaffrey

  • Comparison of 7-Year Results of One-Level vs Two-Level Cervical Disc Arthroplasty and Fusion

    by Matthew F. Gornet, Todd H. Lanman, J. Kenneth Burkus, Scott D. Hodges, Jeffrey R. McConnell, Randall F. Dryer, Francine W. Schranck, Anne G. Copay

  • Radiographic and CT Evaluation of Recombinant Human Bone Morphogenetic Protein-2-Assisted Cervical Spinal Interbody Fusion

    by Luke J. Weisbrod, John D. Leever, J. Kenneth Burkus, Kevin T. Foley, Randall F. Dryer, Paul M. Arnold

  • Two-Level Cervical Disc Arthroplasty with PRESTIGE LP Disc versus Anterior Cervical Discectomy and Fusion: Seven-Year Outcomes of a Prospective, Randomized IDE Clinical Trial

    by Matthew F. Gornet, Todd H. Lanman, J. Kenneth Burkus, Randall F. Dryer, Jeffrey R. McConnell, Scott D. Hodges

  • Retrograde ejaculation following single-level anterior lumbar surgery with or without recombinant human bone morphogenetic protein–2 in 5 randomized controlled trials

    by J. Kenneth Burkus, Randall F. Dryer, John H. Peloza

    Object: The aim of this study was to determine the incidence and assess specific risk factors in the postoperative development of retrograde ejaculation (RE) in men treated for degenerative lumbar disc disease at the L4–5 or L5–S1 level with stand-alone anterior interbody implants with or without recombinant human bone morphogenetic protein–2 (rhBMP-2). Methods: Patients enrolled in 5 prospective, randomized, multicenter FDA-approved investigational device exemption studies were observed for a minimum of 2 years to assess the rate of RE. Five hundred eight men with symptomatic single-level lumbar degenerative disc disease with up to Grade 1 spondylolisthesis underwent anterior lumbar interbody surgery with stand-alone anterior implants at either L4–5 or L5–S1. All patient self-reported and physician-documented adverse events were recorded over the entire course of follow-up. In the investigational groups, 207 patients were treated with an open surgical procedure using dual paired constructs and rhBMP-2 on an absorbable collagen sponge. The control groups (n = 301) were treated with lumbar fusion cage implants and iliac crest autograft or a metal-on-metal disc arthroplasty device. Multivariate analyses of RE were performed to assess the influence of treatment (rhBMP-2), surgical approach, and treated level. Data were analyzed for each trial individually and for the data pooled from the 5 trials. Results: Retrograde ejaculation occurred at the highest rates in the earliest clinical trial. Of the 146 men, 6 (4.1%) developed RE postoperatively. In subsequent studies, the rates of RE ranged from 0% to 2.1%. Combining the data from the 5 trials, RE was reported in 7 (3.4%) of the 207 patients who received the rhBMP-2 treatment compared with 5 (1.7%) of the 301 patients who received the autograft or lumbar disc treatment (p = 0.242, Fisher exact test). Cases of RE were reported in 7 (1.6%) of 445 patients who underwent a retroperitoneal spinal exposure; 5 RE cases were reported in 58 patients (8.6%) who underwent a transperitoneal approach. The difference in surgical approaches was significant (p = 0.007, Fisher exact test). There was no difference in the rate of RE based on the lumbar level exposed (p = 0.739). Multivariate analyses were consistent with the conclusions from Fisher exact tests. In the initial rhBMP-2 trial, after adjusting for effects of surgical approach and treated level, the difference in RE between the treatment groups (rhBMP-2 vs autograft or disc arthroplasty) was not significant (p = 0.177); however, the difference in RE between the retroperitoneal and transperitoneal approaches was significant (p = 0.029). Conclusions: In these 5 prospective randomized trials involving anterior lumbar interbody surgery, the use of rhBMP-2 was associated with a higher incidence of RE (3.4% vs 1.7%) but did not reach statistical significance. Based on surgical approach, the difference in rates of RE was statistically significant. This study reports on the outcomes of 5 prospective randomized FDA-approved investigational device exemption trials. Registration for studies became law in 2007. Four of these trials were completed before the law went into effect. The registration number for the lumbar disc arthroplasty trial is NCT00635843.


  • Blood Serum Antibody Analysis and Long-Term Follow-up of Patients Treated With Recombinant Human Bone Morphogenetic Protein-2 in the Lumbar Spine

    by J. Kenneth Burkus, Matthew F. Gornet, Steven D. Glassman, Paul J. Slosar, Michael K. Rosner, Jeffrey E. Deckey, John Nowak, Brian M. Hatcher

    Prospective, longitudinal cohort study. To examine the incidence of bone morphogenetic protein (BMP)-2 antibody formation in lumbar spine applications and to determine the clinical significance of an antibody response. Immune responses can affect the safety and efficacy profile of recombinant proteins. Type, incidence, and time course of antibody formation were evaluated in clinical studies investigating recombinant human bone morphogenetic protein (rhBMP)-2 in spinal arthrodesis. Analysis of antibody formation to BMP-2, bovine collagen, and human collagen was performed after three prospective clinical studies investigating rhBMP-2 in single-level lumbar spinal arthrodesis. Two studies investigated rhBMP-2 applied to an absorbable collagen sponge at 1.5 mg/cm3 in lumbar interbody fusion (n=449); one study investigated rhBMP-2 applied to a ceramic and collagen compression-resistant matrix at 2.0 mg/cm3 in instrumented posterolateral fusion (n=239). Control patients received iliac crest bone graft (n=360). Two validated enzyme-linked immunosorbent assays were used to test for BMP-2 antibodies. Neutralizing antibodies were assessed using a cell bioassay. The incidence of antibodies to bovine and human collagen was determined. Radiographic and clinical outcome data were assessed to determine whether antibodies were correlated to patient outcomes. BMP-2 antibody rates ranged from 0.8% to 6.4% in rhBMP-2 patients and from 0% to 2.3% in control patients. Formation of BMP-2 antibodies peaked within the first 3 months and returned toward baseline values by 12 months. No neutralizing antibodies were detected. Bovine collagen antibody rates ranged from 12.7% to 18.8% in the rhBMP-2 patients and from 12.9% to 21.2% in the control patients. No antibodies to human collagen were detected. Adverse event rates were similar in antibody-positive and antibody-negative patients. BMP-2 antibodies did not affect bridging bone rates. Formation of anti-BMP-2 antibodies was low and transient. No neutralizing antibodies were observed. Formation of antibodies did not affect fusion success or appear to have clinical sequelae.


  • Recombinant Human Bone Morphogenetic Protein-2 on an Absorbable Collagen Sponge with an Osteoconductive Bulking Agent in Posterolateral Arthrodesis with Instrumentation

    by Edgar Dawson, Hyun W. Bae, J. Kenneth Burkus, Jeffery L. Stambough, Steven D. Glassman

    Background: Recombinant human bone morphogenetic protein-2 (rhBMP-2) on an absorbable collagen sponge has been shown to be a safe and effective replacement for iliac crest bone graft when used with a threaded fusion device in anterior lumbar interbody arthrodesis. Use of rhBMP-2 on an absorbable collagen sponge in posterolateral lumbar arthrodesis requires the addition of a bulking agent to provide resistance against compression and to serve as an osteoconductive scaffold for new bone formation. Methods: We performed a prospective, randomized, multicenter pilot study to investigate the use of rhBMP-2 on an absorbable collagen sponge combined with a ceramic-granule bulking agent as a replacement for autogenous iliac crest bone graft in single-level posterolateral lumbar arthrodesis with instrumentation. The investigational group (twenty-five patients) was treated with a 1.5 mg/mL solution of rhBMP-2 on two strips of absorbable collagen sponge (total dose of rhBMP-2, 12 mg) combined with 10 cm3 of ceramic granules. The control group (twenty-one patients) received iliac crest bone graft. Clinical outcomes were assessed with use of well-established instruments. Radiographs were reviewed to assess consolidation of fusion. Results: Eighty-eight percent (twenty-two) of the twenty-five patients in the investigational group and 86% (eighteen) of the twenty-one patients in the control group were considered to have completed the twenty-four-month follow-up. At all follow-up intervals, there were significant improvements in the clinical outcome measures, including the Oswestry Disability Index (ODI) scores, Short Form-36 scores, and back and leg pain scores, in both groups. At twenty-four months, the improvement in the mean ODI score, as compared with the preoperative score, was 28.2 points in the investigational group and 23.0 points in the control group. By twenty-four months, 95% (eighteen) of nineteen patients in the investigational group compared with 70% (fourteen) of twenty in the control group had a radiographically documented fusion. The overall success rate was 81% (seventeen of twenty-one) in the investigational group and 55% (eleven of twenty) in the control group (p = 0.345). Conclusions: Compared with an iliac crest bone graft, the combination of an absorbable collagen sponge soaked with rhBMP-2 and ceramic granules resulted in trends toward improvements in clinical outcomes and toward a higher rate of radiographic fusion. This combination of an osteoinductive agent with an osteoconductive matrix may be an effective replacement for autograft in single-level posterolateral lumbar arthrodeses with instrumentation. Level of Evidence: Therapeutic Level II. See Instructions to Authors for a complete description of levels of evidence.